4-(4-氧代哌啶-1-羰基)-苯甲酰胺 | 204863-53-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 4-(4-氧代哌啶-1-羰基)-苯甲酰胺
• 中文别名: 3-氧代-4H-1,4-苯并噻嗪-6-羧酸乙酯
• 英文名称: ethyl 3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylate
• 英文别名: ethyl 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylate；ethyl 3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-carboxylate；6-Ethoxycarbonyl-2H-1,4-benzothiazin-3(4H)-one；ethyl 3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate；ethyl 3-oxo-4H-1,4-benzothiazine-6-carboxylate
• CAS: 204863-53-6
• 化学式: C₁₁H₁₁NO₃S
• mdl: MFCD03450523
• 分子量: 237.279
• InChiKey: ANIBMWZLVBRBFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  440.8±45.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-(4-氧代哌啶-1-羰基)-苯甲酰胺 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  EP1466899

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氯-3-硝基苯甲酸 在 palladium on activated charcoal 吡啶 、 硫酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 15.0h， 生成 4-(4-氧代哌啶-1-羰基)-苯甲酰胺
  参考文献：
  名称：

  Quantitative Structure-Activity Relationship Study of N-(3-Oxo-3,4-dihydro-2H-benzo [1,4]thiazine-6-carbonyl)guanidines as Potent Na/H Exchange Inhibitors.

  摘要：

  我们以前曾报道过，N-(4-异丙基-2, 2-二甲基-3-氧代-3, 4-二氢-2H-苯并[1, 4]恶嗪-6-甲酰基)胍（4b）甲磺酸盐（KB-R9032）是一种强效、高水溶性的 Na/H 交换抑制剂。在对 Na/H 交换抑制剂的一系列研究中，我们设计并合成了 N-(3-氧代-3,4-二氢-2H-苯并[1,4]噻嗪-6-羰基)胍（5），作为更有效的高水溶性抑制剂。5 的设计策略基于定量结构-活性关系（QSAR）研究，涉及生物活性与化合物 4 环结构疏水性之间的比例关系。通过 QSAR 分析发现，化合物 5 的药效比化合物 4 高出约五倍。最有效的衍生物是 4-异丙基衍生物的甲磺酸盐 5d（IC50=0.0091μM）。除了体外研究外，5d 对大鼠急性心肌梗塞模型也显示出显著的保护活性。

  DOI：

  10.1248/cpb.48.843

文献信息

• Hydroxamic acid derivatives
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US06713477B1

  公开（公告）日：2004-03-30

  A hydroxamic acid derivative represented by formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which has a matrix metalo-proteinase inhibitor.

  由式（1）表示的羟羧酸衍生物或其前药，或其药用可接受的盐，具有基质金属蛋白酶抑制剂。
• [EN] AMINE COMPOUNDS<br/>[FR] DERIVES D'INDOLE SERVANT D'ANTAGONISTE DE SOMATOSTATINE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004046107A1

  公开（公告）日：2004-06-03

  The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

  本发明提供了一种公式(I)的化合物，其中环A代表一个具有可选取代基的芳香环；B、Y和Ya相同或不同，分别代表一个键等；R1和R2相同或不同，每个代表一个氢原子等；R3代表一个氢原子等；R4和R5相同或不同，每个代表一个氢等；R6代表一个可选有取代基的吲哚基团；Z和Za相同或不同，每个代表一个氢原子等；或其盐或前药，具有生长抑素受体结合抑制活性，并且用于预防或治疗与生长抑素相关的疾病。
• Indole derivatives as somatostatin agonists or antagonists
  申请人：Abe Hidenori

  公开号：US20060223826A1

  公开（公告）日：2006-10-05

  The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R 1 and R 2 are the same or different and each represents a hydrogen atom, etc.; R 3 represents a hydrogen atom, etc.; R 4 and R 5 are the same or different and each represents a hydrogen, etc.; R 6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

  本发明提供了一种化合物(I)的公式，其中环A代表一种芳香环，可选地具有取代基; B、Y和Ya相同或不同，每个代表一种键等; R1和R2相同或不同，每个代表一个氢原子等; R3代表一个氢原子等; R4和R5相同或不同，每个代表一个氢等; R6代表一种吲哚基，可选地具有取代基; Z和Za相同或不同，每个代表一个氢原子等; 或其盐或前药，具有生长抑素受体结合抑制活性，并用于预防和/或治疗与生长抑素相关的疾病。
• Discovery of a Plasmodium falciparum Glucose-6-phosphate Dehydrogenase 6-phosphogluconolactonase Inhibitor (<i>R</i>,<i>Z</i>)-<i>N</i>-((1-Ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]thiazine-6-carboxamide (ML276) That Reduces Parasite Growth in Vitro
  作者：Janina Preuss、Patrick Maloney、Satyamaheshwar Peddibhotla、Michael P. Hedrick、Paul Hershberger、Palak Gosalia、Monika Milewski、Yujie Linda Li、Eliot Sugarman、Becky Hood、Eigo Suyama、Kevin Nguyen、Stefan Vasile、Eduard Sergienko、Arianna Mangravita-Novo、Michael Vicchiarelli、Danielle McAnally、Layton H. Smith、Gregory P. Roth、Jena Diwan、Thomas D.Y. Chung、Esther Jortzik、Stefan Rahlfs、Katja Becker、Anthony B. Pinkerton、Lars Bode

  DOI：10.1021/jm300833h

  日期：2012.8.23

  A high-throughput screen of the NIH's MLSMR collection of similar to 340000 compounds was undertaken to identify compounds that inhibit Plasmodium falciparum glucose-6-phosphate dehydrogenase (Pf G6PD). PfG6PD is important for proliferating and propagating P. falciparum and differs structurally and mechanistically from the human orthologue. The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, rate-limiting step in the pentose phosphate pathway (PPP), a key metabolic pathway sustaining anabolic needs in reductive equivalents and synthetic materials in fast-growing cells. In P. falciparum, the bifunctional enzyme glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (Pf GluPho) catalyzes the first two steps of the PPP. Because P. falciparum and infected host red blood cells rely on accelerated glucose flux, they depend on the G6PD activity of Pf GluPho. The lead compound identified from this effort, (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbon-amide, 11 (ML276), is a submicromolar inhibitor of Pf G6PD (IC50 = 889 nM). It is completely selective for the enzyme's human isoform, displays micromolar potency (IC50 = 2.6 mu M) against P. falciparum in culture, and has good drug-like properties, including high solubility and moderate microsomal stability. Studies testing the potential advantage of inhibiting Pf G6PD in vivo are in progress.
• HYDROXAMIC ACID DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1173427B1

  公开（公告）日：2006-04-05